Healthcare
New Abu Dhabi clinical trials using AI to have ‘massive’ impact on healthcare
Oracle, AstraZeneca and M42 are using AI and linked health data to identify hypertension patients and accelerate clinical-trial recruitment in Abu Dhabi.
Oracle, AstraZeneca and Abu Dhabi-based M42 have partnered to apply artificial intelligence to clinical-trial operations and hypertension care in the UAE. The initiative combines Oracle’s cloud infrastructure and AI capabilities with AstraZeneca’s scientific-development expertise and M42’s healthcare data and clinical networks.
The first program focuses on identifying patients with uncontrolled hypertension, supporting their care and improving recruitment for relevant clinical trials. The companies aim to connect electronic health records with clinical-trial systems so clinicians can identify eligible patients more efficiently.
The collaboration could also enable more healthcare providers to participate in research by making trial identification and recruitment part of routine clinical workflows. Oracle expects the approach to reduce the time and cost associated with conducting trials.
The project is significant because it links patient care, real-world health data and pharmaceutical research in a single workflow. It also illustrates how AI is being deployed in the UAE to improve clinical research efficiency rather than only automate administrative tasks.
Original source: The National